1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ribomic, Inc.

Ribomic, Inc.

TTSE:4591
65.00
JPY
-1.00
(-1.52%)
4.78BMarket Cap
Nov 12Next Earn
Ribomic, Inc.
TSE:4591
(Tokyo Stock Exchange)

Recent

price

65.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
14.45
40.94
9.4
7.08
4.78
0.55
7.61
3.58
2.88
2.12
- -
0.05
0.06
- -
Revenue per Share
-20.24
0.88
-24.92
-48.83
-55.61
-58.22
-53.62
-46.17
-59.95
-53.14
-28.7
-25.21
-23.07
- -
Basic EPS, GAAP
-19.05
11.26
-28.73
-55.66
-52.4
-59.06
-59.53
-44.75
-53.72
-55.69
-26.77
-25.48
-22.58
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
29.06
254.49
231.21
183.56
156.7
103.06
124.23
215.08
164.36
122.85
94.2
68.26
52.31
- -
Book Value per Share
29.02
254.47
231.2
183.54
156.67
102.89
124.14
215.08
164.36
122.85
94.2
68.26
52.31
- -
Tangible Book Value per Share
10
12
13
13
14
14
16
26
28
31
36
40
50
50
Basic Weighted Avg Shares
151
480
122
94
65
8
121
92
81
66
- -
2
3
- -
Sales/Revenue/Turnover
-256.56
7.5
-420.46
-838.09
-1,390.29
-11,682.3
-753.45
-1,347.98
-2,160.59
-2,707.39
- -
-49,861.84
-40,237.73
- -
Operating Margin (%)
12
18
14
36
26
28
18
27
16
- -
11
1
4
- -
Depreciation Expense
-212
10
-323
-647
-753
-837
-855
-1,187
-1,685
-1,653
-1,024
-1,019
-1,145
- -
Net Income, GAAP
- -
11.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-140.08
2.15
-265.2
-689.54
-1,163.42
-10,524.9
-704.4
-1,290.95
-2,082.28
-2,505.73
- -
-48,359.71
-38,178.67
- -
Profit Margin (%)
304
3,231
2,968
2,376
2,140
2,416
2,087
5,933
4,648
4,343
3,351
3,005
2,793
- -
Working Capital
- -
- -
- -
- -
- -
1,000
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
354
3,263
3,039
2,439
2,227
1,483
2,181
6,003
4,694
4,384
3,391
3,044
2,841
- -
Total Equity
- -
0.3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
0.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
0.57
-10.26
-23.61
-32.28
-45.1
-46.67
-29.01
-31.5
-36.42
-26.34
-31.67
-38.93
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
54
57
Market Capitalization
4,877
4,779
3,449

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
3,322
2,928
- -
Cash, Cash Equivalents & STI
3,222
2,827
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
4
3
- -
Total Current Liabilities
132
135
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.25%
-13.59%
-6.65%
Free Cash Flow
16.45%
3.55%
8.86%
Net Income, GAAP
18.25%
2.78%
12.41%
Sales/Revenue/Turnover
- -
- -
42.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
3
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-25.21
2026
- -
- -
- -
- -
-23.07
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ribomic Inc. (4591.T), founded in 2003 and headquartered in Tokyo, Japan, engages in the discovery and development of pharmaceutical compounds using proprietary RNA aptamer therapeutics via its Ribomic Aptamer Refined Therapeutics (RiboART) platform, which enables shape-capturing binding to target proteins for applications across various disease areas including ophthalmologic disorders, bone diseases, and wet age-related macular degeneration (wet AMD); core products in clinical development include RBM-007 (umędaptanib pegol), an anti-FGF2 aptamer for achondroplasia (early Phase II in Japan with dosing initiated in Cohort 2 and orphan drug designation granted in April 2025) and wet AMD (Phase II trials such as SUSHI, TOFU, RAMEN, and TEMPURA completed), alongside self-discovery and co-discovery pipelines targeting unmet needs through collaborations. The company operates primarily in Japan with a U.S. subsidiary (RIBOMIC USA Inc.) and serves pharmaceutical partners and academic institutions globally. Recent developments encompass a January 2024 joint research agreement with Ajinomoto Co., Inc. for aptamer technologies in eye and bone diseases (with successful pharmacokinetic extension results announced May 2025), a July 2024 cooperative research agreement with The University of Tokyo on ophthalmologic diseases, completion of patient enrollment in RBM-007's early Phase II achondroplasia study in August 2024, and funding of approximately ¥4.19 million from SMBC Nikko Securities Inc. in March 2024; ongoing alliances include Otsuka Pharmaceutical, AJU Pharma, and others for licensing and commercialization.